Physician profile
Benjamin D Currie
NPI 1538457130
$1,374.84
in general payments reported to CMS, 2019-2025
19 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $68.29 · 2021: $376 · 2022: $155 · 2023: $354 · 2024: $92.49 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $568 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $567.79 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lensar, INC. | $261.31 | 2021 | |
| Rxsight INC | $154.36 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Alcon Vision LLC | $142.04 | 2020-2023 | Hydrus Microstent |
| Rayner Intraocular Lenses Limited | $117.40 | 2023-2024 | Rayone Aspheric, Omidria, Rayone Emv |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $115.43 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $109.04 | 2019-2025 | Eylea Hd |
| Allergan, INC. | $68.02 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $55.76 | 2022-2024 | Envista Mx60 Iol, Vyzulta |
| Dompe US, INC. | $48.35 | 2022-2025 | Oxervate |
| Genentech USA, INC. | $42.85 | 2022-2025 | Vabysmo |
| Sun Pharmaceutical Industries INC. | $38.21 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $37.46 | 2019-2022 | |
| Biotissue Holdings INC. | $36.57 | 2021-2023 | |
| Kala Pharmaceuticals, INC. | $35.08 | 2019-2021 | |
| Glaukos Corporation | $29.09 | 2022-2025 | Idosetr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $24.43 | 2023 | Catalys System |
| Tarsus Pharmaceuticals, INC. | $22.17 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $20.90 | 2021 | |
| Abbvie INC. | $16.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Currie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.